Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;95(1):143-152.
doi: 10.1111/cen.14468. Epub 2021 Apr 4.

Insulin-like growth factor-1, growth hormone and disease outcomes in acromegaly: A population study

Melissa Thomas  1 , Ellen Berni  1 , Sara Jenkins-Jones  1 , Sarah Wensley  2 , Chris D Poole  1 , Craig J Currie  1   3 , Jack Brownrigg  2 , John Ayuk  4 , D Aled Rees  5
Affiliations

Insulin-like growth factor-1, growth hormone and disease outcomes in acromegaly: A population study

Melissa Thomas et al. Clin Endocrinol (Oxf). 2021 Jul.

Abstract

Context: A lack of consensus remains about the relative importance of insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in predicting adverse outcomes in patients with acromegaly.

Objective: To describe the differing association between IGF-1 and GH and major disease outcomes in acromegaly.

Design: Retrospective cohort study.

Patients: United Kingdom National Health Service patients with acromegaly who had an IGF-1 and/or a GH measurement recorded following diagnosis, prior to December 2019.

Measurements: A composite endpoint including all-cause mortality (ACM), type 2 diabetes (DM), major adverse cardiovascular events (MACE) or cancer was the primary outcome. These outcomes were also analysed individually. Follow-up period was capped at 5 years.

Results: A maximum of 417 cases and 332 cases were eligible for the IGF-1 and GH analyses, respectively, comprising 1041.5 and 938.9 years of follow-up. There was a direct association between increased IGF-1 concentration and adjusted event risk for the composite endpoint (hazard ratio [HR] = 1.2; 95% confidence interval [CI] = 1.02-1.5); in GH, the HR was 1.1 (1.0-1.2). For the individual endpoints in relation to IGF-1 level, the HRs were ACM (1.2; 0.93-1.5), MACE (1.2; 0.64-2.1), DM (1.53; 1.09-2.2) and cancer (1.3; 0.95-1.7). For GH, the HRs were ACM (1.1; 0.97-1.2), MACE (0.99; 0.73-1.3), DM (1.1; 0.99-1.2) and cancer (0.90; 0.66-1.2).

Conclusions: In this contemporary data set with extended follow-up, IGF-1 and GH concentrations showed an association with major adverse outcomes from acromegaly.

Keywords: Insulin-like growth factor 1; acromegaly; cardiovascular diseases; diabetes mellitus type 2; growth hormone; mortality; neoplasms.

PubMed Disclaimer

References

REFERENCES

    1. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20:4-9.
    1. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31:301-342.
    1. Sughrue ME, Chang EF, Gabriel RA, Aghi MK, Blevins LS. Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary. 2011;14:276-283.
    1. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2008;93:61-67.
    1. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.

Publication types

Grants and funding

LinkOut - more resources